Resultst of the Multicentre study of Nasopharyngeal Isolates of Haemophilus influenzae from Healthy Children in Day-Care Centers

Clinical Microbiology and Antimicrobial Chemotherapy. 2002; 4(1):33-41

​ Stratchounski L.S., Krechikova O.I., Reshedko G.K., Stetsiouk O.U., Egorova O.A., Kandalov M.M., Boyko L.M., Ryabkova E.L., Tarasova G.D., Blokhin B.M.
antimicrobial resistance Haemophilus influenzae carriage
Section
Antimicrobial Resistance
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2002; 4(1):33-41

Abstract

The rates of nasopharyngeal carriage of Haemophilus influenzae and epidemiology of its antimicrobial resistance in healthy children from day-care centers have been investigated. The overall rate of nasopharyngeal H.influenzae carriage was 44%. The susceptibility testing was performed by E-tests. The resistance rates (including intermediately resistant strains) was: 2,1% to ampicillin, 0,6% to amoxycillin/clavulanate, 0,6% to cefaclor, 18,7 to clarithromycin (only intermediate resistance), 20,9% to trymethoprim/sulphamethoxazole. The antimicrobial resistance profiles varied in different centers. The clinical use of trimethoprim/sulphamethoxazole in respiratory tract infections should be restricted because of the high resistance of H.influenzae to this antimicrobial.

  • 1. Felmingam D. Antibiotic resistance: Do we need new therapeutic approaches? Chest 1995; 108:70-8.
  • 2. Катосова Л. К., Волков И.К., Иобидзе М.В., Клюкина Л.П., Сидорина Т.М. Особенности микробной флоры бронхиального секрета детей с хроническими бронхолегочными заболеваниями и муковисцидозом и их антибактериальная терапия. Вопр охр мат дет 1987; 8:9-14.
  • 3. Faustova M, Reztsova Y., Solodub T., Moshkevitch I., Vishniakova L. Sensitivity of Streptococcus pneumoniae and Haemophilus influenzae strains isolated from respiratory patients. Clin Microb Infect 1999; 5:274.
  • 4. Таточенко В.К., Катосова Л.К., Федоров А.М. Антибактериальная терапия острых респираторных заболеваний. Рос педиатр журн 1998; 2:61-5.
  • 5. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing; Eleventh Informational Supplement. NSSLS Document M100-S11 2001; 21:98-9.
  • 6. Leroy J., Dupont M., Mermet F., Amsallen D., Jaeger F., Henon T., et al. Streprococcus pneumoniae (SP) and Haemophilus influenzae (HI) nasopharyngeal (NP) carriage in day-care centers in Eeastern France. Proceedings of the 37th ICAAC; 1997 Sept 28–Oct 1; Toronto, Ontario, Canada; 1997.
  • 7. Liassine N., Gervaix A., Hegi R., Strautman G., Suter S., Auckenthaler R. Antimicrobial susceptibility of bacterial pathogens in the oropharynx of healthy children. Eur J Clin Microbiol Infect Dis 1999; 18:217-20.
  • 8. Mastro T., Nomani N., Ishad Z., Ghafoor A., Fshaukat N., Esko E., et al. Use of nasopharyngeal isolates of Streptococcus pneumoniae and Haemophilus influenzae from children in Pakistan for surveillance for antimicrobial resistance. Pediatr Infect Dis J 1993; 12:824-30.
  • 9. Vites M., Garcia M, Saenz P., Mora M., Mata L., Saharwal H., et al. Nasopharyngeal colonization in Costa Rican children during the first year of life. Pediatr Infect Dis J 1997; 16:852-8.
  • 10. Harabuchi Y., Faden H., Yamanaka N., Duffy L., Wolf J., Krystofik D., et al. Nasopharyngeal colonization with nontypeable Haemophilus influenzae and recurrent otitis media. J Infect Dis 1994; 170:862-6.
  • 11. Homoe P., Prag J., Farholt S., Henrichsen J., Horusleth A., Kilian M., Jensen J. High rate of nasopharyngeal carriage of potential pathogens among children in Greenland: results of a clinical survey of middle-ear disease. Clin Infect Dis 1996; 23:1081-90.
  • 12. Faden H., Duffy L., Wasielewski R., Wolf J., Krystofik D., Tung Y., et al. Relationship between nasopharyngeal colonization and the development of otitis media in children. J Infect Dis 1997; 175:1440-5.
  • 13. Faden H., Doern G., Wolf J., Blocker M. Antimicrobial susceptibility of nasopharyngeal isolates of potential pathogens recovered from infants before antibiotic therapy implications for the management of otitis media. Pediatr Infect Dis J 1994; 13:609-12.
  • 14. Antibiotic resistance among nasopharyngeal isolates of Streptococcus pneumoniae and Haemophilus influenzae – Bangui, 1995. MMWR 1997; 46:62-4.
  • 15. Felmingham D., Gruneberg R. N., the Alexander Project Group. The Alexander Project 1996–1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. JAC 2000; 45:191-203.
  • 16. Groot R., Dzoliic-Danilovic G., Kligeren B., Goessens W., Neyens H. Antibiotic resistance in Haemophilus influenzae: mechanisms, clinical importance and consequencesfor therapy. Eur J Pediatr 1991; 150:534-46.
  • 17. Jones R., Jacobs M., Washington J., Pfaller M. A 1994–95 survey of Haemophilus influenzae susceptibility to ten orally administered agents. Diagn Microbiol Infect Dis 1997; 27:75-83.
  • 18. Burry A., Fuchs P., Pfaller M. Susceptibility of в-lactamase-producting and-nonproducting ampicillin-resistance strains of Haemophilus influenzae to ceftibuten, cefaclor, cefuroxime, cefixime, cefotaxime and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 1993; 37:14-8.
  • 19. Ishiwada N., Kuruki H., Ishikawa N., Sugimoto K., Koori Y., Suguda Y., et al. Characteristics of b-lactamase-producing and amoxicillin-clavulanat-resistant strains of Haemophilus influenzae isolated from pediatric patients. J Infect Chemother 1998; 4:112-5.
  • 20. Talon D., Estavoyer J., Dupont M., Leroy J. Phenotypic and genotypic characterization of Haemophilus influenzae strains isolated from the nasopharyngeal specimens of children in day-care centers in eastern France. Proceedings of the 38th ICAAC; 1998 Sept 24–27; San Diego, California; 1998.
  • 21. Bajanca-Lavado M., Casin I., Vaz Pato M., the Multicentre Study group. Antimicrobial resistance and epidemiological study of Haemophilus influenzae strains isolated in Portugal. J Antimicrob Chemother 1996; 38:615-25.
  • 22. Belongia E., Sullivan B., Reed K., Chyou P., Vierkant R., Schwartz B. Risk factors for penicillin-nonsusceptible sterptococcus pneumoniae and b-lactamase-producing Haemophilus influenzae carriage in children attending day-care. Proceedings of the 38th ICAAC; Sept 24–27; San-Diego, California; 1998.
  • 23. Crokaert F., Aoun M., Duchateau V., Goossens H., Grenier P., Vandermies A., Klastersky J. Are macrolide active against Haemophilus influenzae? Are in vitro tests reliable? Proceedings of the 35th ICAAC, Sept 17–50 1995; San Francisco, California; 1995.
  • 24. Hardy D., Hensey D., Beyer J., et al. Comparative in vitro activities of 14-, 15- and 16-membered macrolides. Antimicrob Agents Chemother 1988; 32:1710-9.
  • 25. Barry A. Antibacterial activity of clarithromycin, 14-hydroxy clarithomycin and five other oral agents against respiratory pathogens from outpatients within the United States. Proceedings of the Second International Conference on the macrolides, azalides, and streptogramins, Jan 19–22 1994; Venice, Italy; 1994.
  • 26. Chin N., Della-Latta P., Whittier S., Neu H. in vitro activity of clarithromycin and 14-hydroxy clarithromycin versus H. influenzae and Group B Streptococcus in the New York Area. Proceedings of the Second International Conference on the macrolides, azalides, and streptogramins, Jan 19–22 1994; Venice, Italy; 1994.
  • 27. Gustavasan l., Crafft J. Pharmacokinetic profile of clarithromycin suspension for children: an overview. Proceedings of the Second International Conference on the macrolides, azalides, and streptogramins, Jan 19–22 1994; Venice, Italy; 1994.
  • 28. Scaglione F., Demartini G., Fraschini F. Distribution of clarithromycin in intracellular and extravascular sites of infection: an overview. Proceedings of the Second International Conference on the macrolides, azalides, and streptogramins, Jan 19–22 1994; Venice, Italy; 1994.
  • 29. Moola S., Hagberg L., Churchyard A., Sedani S., Staley H., the Raxar Study group. Comparison of grepafloxacin with clarithromycin in the tratment of community-acquired pneumonia. Proceedings of the 38th ICAAC; Sept 24–27; San-Diego, California; 1998.
  • 30. Chodosh S., Schreurs A., Siami G., Barkman H., Ansueto A., Shan M., et al. Efficacy of oral ciprofloxacin vs. clarithromycin for the treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis 1998; 27:730-8.
  • 31. Gervaix A., Liassine N., Hegi R., Auckenthaler R., Suter S. Oropharyngeal carrieage and antibiotic susceptibility of bacterial pathogens in healthy children. Proceedings of the 35th ICAAC, Sept 17–50 1995; San Francisco, California; 1995.
  • 32. Young R., Gonzalez J., Sorkin E. Roxithromycin. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1989; 37:8-41.
  • 33. Cooper B., Mullins P., Jones M., Lang S. Clinical efficacy of roxithromycin in the treatment of adults with upper and lower respiratory tract infection due to Haemophilus influenzae. Drug Invest 1994; 7:299-314.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared